Market Cap 7.43M
Revenue (ttm) 0.00
Net Income (ttm) -8.77M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 88,300
Avg Vol 161,052
Day's Range N/A - N/A
Shares Out 4.79M
Stochastic %K 100%
Beta 0.16
Analysts Sell
Price Target $25.00

Company Profile

Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer's, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-pe...

Industry: Biotechnology
Sector: Healthcare
Phone: 844 722 6333
Address:
3480 Peachtree Road NE, Second Floor, Suite 103, Atlanta, United States
JimmyOcarri
JimmyOcarri Aug. 17 at 8:39 PM
0 · Reply
hiwatt
hiwatt Aug. 15 at 5:26 PM
$ALZN This is what accumulation looks like. In 90 minutes, 36,758 shares of green buys.
0 · Reply
ka1954
ka1954 Aug. 14 at 6:42 PM
$ALZN that delisting requirement has been put on hold by SEC indefinitely
0 · Reply
hiwatt
hiwatt Aug. 14 at 2:56 AM
$ALZN Well it's been one year since the Harvard paper on lithium in the brain has been published. Like this Neurologist in the video says, look for clinical trials of low dose lithium salts. One year later and only one company has completed a lithium brain trial and only one company has started a new lithium brain study, Alzn. Even Harvard has not started or posted a lithium study on clinical trials, and John Hopkins has posted a lithium study on clinical trials, but has not started recruiting yet. Even when Alzn reported positive results on their lithium in the brain study on tpo of all the euphoria of the Harvard Nature paper, the stock still sold off. I guess Rodney Dangerfield was right, no respect. https://www.instagram.com/reel/DNOzLU5Sqn2/?hl=en
0 · Reply
H3D3RA
H3D3RA Aug. 10 at 9:06 PM
0 · Reply
hiwatt
hiwatt Aug. 7 at 4:15 PM
$ALZN WOW, Institutional ownership just just to over 30% with the additional of KMT Wealth Management. They have bought 1, 329,100 shares, which is over 25% of the float.
0 · Reply
WC25
WC25 Aug. 6 at 6:12 PM
$GPUS @Ault Mr. Ault, good morning. Why did Hyperscale Data Inc just indirectly (through Ault Lending LLC) do a Purchase Agreement (Cash BAILOUT infusion) with Alzamend Neuro Inc $ALZN for an initial $7.5 Million worth of their new Series D Convertible Preferred Stock, with another $2.5 Million due ten days after the registration statement is effective, and the remaining $15 Million to be purchased in equal tranches over the next 15 months...none of which even have a Dividend attached!? Ault Lending LLC is owned by Ault Capital Group Inc, which is a wholly owned subsidiary of Hyperscale Data Inc. By potentially later this month alone, Ault Lending LLC will have taken a roughly 68% stake in ALZN once the new (convertible adjusted) 10,335,000 shares are added to the current est outstanding amount of 4.79 Million shares 'should it be authorized to convert all-at-once'...potentially climbing later to 84% ownership once the full $25 Million cash infusion is accounted for (cont'd)
6 · Reply
hiwatt
hiwatt Aug. 5 at 6:45 PM
$ALZN Stock options acquired by CEO, 450,000 shares. https://d1io3yog0oux5.cloudfront.net/alzamend/sec/0001214659-26-009586/0001214659-26-009586.pdf
1 · Reply
hiwatt
hiwatt Aug. 4 at 2:13 PM
$ALZN This funding, along with stock trading above a dollar and marketcap above $5M, pretty much takes the reverse split off the table.
0 · Reply
hiwatt
hiwatt Aug. 4 at 12:04 PM
$ALZN THe Lawsuit between Alzn vs Biorasi continues today. Biorasi was the CRO that apparently botched the AL002 clinical trial. From what I can gather a judge threw out one of the claims, but is allowing Alzn to continue on for breach on contract on the other 5 claims. https://cases.justia.com/federal/district-courts/florida/flsdce/1:2025cv20481/683068/106/0.pdf?ts=1769854003
0 · Reply
Latest News on ALZN
Alzamend Neuro Annual report: Q4 2026

Jul 22, 2026, 7:00 AM EDT - 26 days ago

Alzamend Neuro Annual report: Q4 2026


Alzamend Neuro Slides: Corporate presentation

Jul 21, 2026, 7:00 AM EDT - 27 days ago

Alzamend Neuro Slides: Corporate presentation


Alzamend Neuro Slides: Corporate presentation

Mar 26, 2026, 8:00 AM EDT - 5 months ago

Alzamend Neuro Slides: Corporate presentation


Alzamend Neuro initiates Phase II trial of AL001 study

2026-03-16T12:15:09.000Z - 5 months ago

Alzamend Neuro initiates Phase II trial of AL001 study


Alzamend Neuro Quarterly report: Q3 2026

Mar 11, 2026, 8:00 AM EDT - 5 months ago

Alzamend Neuro Quarterly report: Q3 2026


Alzamend Neuro Proxy statement: Proxy filing

Feb 26, 2026, 7:00 AM EST - 6 months ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Proxy statement: Proxy filing

Feb 26, 2026, 7:00 AM EST - 6 months ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Proxy statement: Proxy filing

Feb 9, 2026, 7:00 AM EST - 6 months ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Quarterly report: Q2 2026

Dec 9, 2025, 7:00 AM EST - 8 months ago

Alzamend Neuro Quarterly report: Q2 2026


Alzamend Neuro Quarterly report: Q1 2026

Sep 10, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Quarterly report: Q1 2026


Alzamend Neuro Annual report: Q4 2025

Jul 22, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Annual report: Q4 2025


Alzamend Neuro Earnings release: Q4 2025

Jul 22, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Earnings release: Q4 2025


Alzamend Neuro Stock (ALZN) Rockets 145% on Study Update

2025-05-29T20:25:00.000Z - 1 year ago

Alzamend Neuro Stock (ALZN) Rockets 145% on Study Update


Alzamend Neuro initiates first Phase II trial of AL001

2025-05-13T12:17:57.000Z - 1 year ago

Alzamend Neuro initiates first Phase II trial of AL001


Alzamend Neuro trading halted, news pending

2025-05-09T23:50:59.000Z - 1 year ago

Alzamend Neuro trading halted, news pending


Alzamend Neuro announces 1-for-9 reverse stock split

2025-05-08T12:24:11.000Z - 1 year ago

Alzamend Neuro announces 1-for-9 reverse stock split


Alzamend Neuro Announces Reverse Stock Split

May 8, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Announces Reverse Stock Split


Alzamend Neuro Registration statement: Registration filing

Mar 27, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Registration statement: Registration filing


Alzamend Neuro Proxy statement: Proxy filing

Mar 19, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Proxy statement: Proxy filing

Mar 17, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Proxy statement: Proxy filing

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Registration statement: Registration filing

Mar 13, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Registration statement: Registration filing


Alzamend Neuro Quarterly report: Q3 2025

Mar 10, 2025, 8:00 AM EDT - 1 year ago

Alzamend Neuro Quarterly report: Q3 2025


Alzamend Neuro Proxy statement: Proxy filing

Feb 28, 2025, 7:00 AM EST - 1 year ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Quarterly report: Q2 2025

Dec 11, 2024, 7:00 AM EST - 1 year ago

Alzamend Neuro Quarterly report: Q2 2025


Alzamend Neuro Earnings release: Q2 2025

Dec 11, 2024, 7:00 AM EST - 1 year ago

Alzamend Neuro Earnings release: Q2 2025


Alzamend Neuro Quarterly report: Q1 2025

Sep 11, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Quarterly report: Q1 2025


Alzamend Neuro Annual report: Q4 2024

Jul 30, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Annual report: Q4 2024


Alzamend Neuro Registration statement: Registration filing

Jul 3, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Registration statement: Registration filing


Alzamend Neuro Registration statement: Registration filing

Jun 26, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Registration statement: Registration filing


Alzamend Neuro Proxy statement: Proxy filing

Jun 11, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Registration statement: Registration filing

Jun 3, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Registration statement: Registration filing


Alzamend Neuro Proxy statement: Proxy filing

May 31, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Proxy statement: Proxy filing

May 10, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Proxy statement: Proxy filing

May 1, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Proxy statement: Proxy filing

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Quarterly report: Q3 2024

Mar 25, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Quarterly report: Q3 2024


Alzamend Neuro Proxy statement: Proxy filing

Mar 13, 2024, 8:00 AM EDT - 2 years ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Quarterly report: Q2 2024

Dec 15, 2023, 7:00 AM EST - 2 years ago

Alzamend Neuro Quarterly report: Q2 2024


Alzamend Neuro Quarterly report: Q1 2024

Sep 13, 2023, 8:00 AM EDT - 3 years ago

Alzamend Neuro Quarterly report: Q1 2024


Alzamend Neuro Proxy statement: Proxy filing

Sep 1, 2023, 8:00 AM EDT - 3 years ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Proxy statement: Proxy filing

Aug 24, 2023, 8:00 AM EDT - 3 years ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Proxy statement: Proxy filing

Aug 10, 2023, 8:00 AM EDT - 3 years ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Registration statement: Registration filing

Aug 2, 2023, 8:00 AM EDT - 3 years ago

Alzamend Neuro Registration statement: Registration filing


Alzamend Neuro Annual report: Q4 2023

Jul 27, 2023, 8:00 AM EDT - 3 years ago

Alzamend Neuro Annual report: Q4 2023


Alzamend Neuro Proxy statement: Proxy filing

Mar 31, 2023, 8:00 AM EDT - 3 years ago

Alzamend Neuro Proxy statement: Proxy filing


Alzamend Neuro Quarterly report: Q3 2023

Mar 15, 2023, 8:00 AM EDT - 3 years ago

Alzamend Neuro Quarterly report: Q3 2023


Alzamend Neuro Quarterly report: Q2 2023

Dec 12, 2022, 7:00 AM EST - 4 years ago

Alzamend Neuro Quarterly report: Q2 2023


Alzamend Neuro Quarterly report: Q1 2023

Sep 13, 2022, 8:00 AM EDT - 4 years ago

Alzamend Neuro Quarterly report: Q1 2023


Alzamend Neuro Annual report: Q4 2022

Jul 19, 2022, 8:00 AM EDT - 4 years ago

Alzamend Neuro Annual report: Q4 2022


Alzamend Neuro Quarterly report: Q3 2022

Mar 15, 2022, 8:00 AM EDT - 4 years ago

Alzamend Neuro Quarterly report: Q3 2022


Alzamend Neuro Quarterly report: Q2 2022

Dec 13, 2021, 7:00 AM EST - 5 years ago

Alzamend Neuro Quarterly report: Q2 2022


Alzamend Neuro Quarterly report: Q1 2022

Sep 13, 2021, 8:00 AM EDT - 5 years ago

Alzamend Neuro Quarterly report: Q1 2022


Alzamend Neuro Annual report: Q4 2021

Jul 29, 2021, 8:00 AM EDT - 5 years ago

Alzamend Neuro Annual report: Q4 2021


Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today

Jul 12, 2021, 6:00 AM EDT - 5 years ago

Alzamend Neuro, Inc. to Ring Nasdaq Opening Bell Today


Alzamend Neuro Announces Pricing of Initial Public Offering

Jun 14, 2021, 5:49 PM EDT - 5 years ago

Alzamend Neuro Announces Pricing of Initial Public Offering


JimmyOcarri
JimmyOcarri Aug. 17 at 8:39 PM
0 · Reply
hiwatt
hiwatt Aug. 15 at 5:26 PM
$ALZN This is what accumulation looks like. In 90 minutes, 36,758 shares of green buys.
0 · Reply
ka1954
ka1954 Aug. 14 at 6:42 PM
$ALZN that delisting requirement has been put on hold by SEC indefinitely
0 · Reply
hiwatt
hiwatt Aug. 14 at 2:56 AM
$ALZN Well it's been one year since the Harvard paper on lithium in the brain has been published. Like this Neurologist in the video says, look for clinical trials of low dose lithium salts. One year later and only one company has completed a lithium brain trial and only one company has started a new lithium brain study, Alzn. Even Harvard has not started or posted a lithium study on clinical trials, and John Hopkins has posted a lithium study on clinical trials, but has not started recruiting yet. Even when Alzn reported positive results on their lithium in the brain study on tpo of all the euphoria of the Harvard Nature paper, the stock still sold off. I guess Rodney Dangerfield was right, no respect. https://www.instagram.com/reel/DNOzLU5Sqn2/?hl=en
0 · Reply
H3D3RA
H3D3RA Aug. 10 at 9:06 PM
0 · Reply
hiwatt
hiwatt Aug. 7 at 4:15 PM
$ALZN WOW, Institutional ownership just just to over 30% with the additional of KMT Wealth Management. They have bought 1, 329,100 shares, which is over 25% of the float.
0 · Reply
WC25
WC25 Aug. 6 at 6:12 PM
$GPUS @Ault Mr. Ault, good morning. Why did Hyperscale Data Inc just indirectly (through Ault Lending LLC) do a Purchase Agreement (Cash BAILOUT infusion) with Alzamend Neuro Inc $ALZN for an initial $7.5 Million worth of their new Series D Convertible Preferred Stock, with another $2.5 Million due ten days after the registration statement is effective, and the remaining $15 Million to be purchased in equal tranches over the next 15 months...none of which even have a Dividend attached!? Ault Lending LLC is owned by Ault Capital Group Inc, which is a wholly owned subsidiary of Hyperscale Data Inc. By potentially later this month alone, Ault Lending LLC will have taken a roughly 68% stake in ALZN once the new (convertible adjusted) 10,335,000 shares are added to the current est outstanding amount of 4.79 Million shares 'should it be authorized to convert all-at-once'...potentially climbing later to 84% ownership once the full $25 Million cash infusion is accounted for (cont'd)
6 · Reply
hiwatt
hiwatt Aug. 5 at 6:45 PM
$ALZN Stock options acquired by CEO, 450,000 shares. https://d1io3yog0oux5.cloudfront.net/alzamend/sec/0001214659-26-009586/0001214659-26-009586.pdf
1 · Reply
hiwatt
hiwatt Aug. 4 at 2:13 PM
$ALZN This funding, along with stock trading above a dollar and marketcap above $5M, pretty much takes the reverse split off the table.
0 · Reply
hiwatt
hiwatt Aug. 4 at 12:04 PM
$ALZN THe Lawsuit between Alzn vs Biorasi continues today. Biorasi was the CRO that apparently botched the AL002 clinical trial. From what I can gather a judge threw out one of the claims, but is allowing Alzn to continue on for breach on contract on the other 5 claims. https://cases.justia.com/federal/district-courts/florida/flsdce/1:2025cv20481/683068/106/0.pdf?ts=1769854003
0 · Reply
hiwatt
hiwatt Aug. 3 at 8:39 PM
$ALZN $$$.7.5M--https://ir.alzamend.com/sec-filings/all-sec-filings/content/0001214659-26-009469/0001214659-26-009469.pdf
0 · Reply
hiwatt
hiwatt Jul. 29 at 12:40 AM
$ALZN https://www.tipranks.com/news/company-announcements/alzamend-neuros-new-lithium-study-puts-al001-in-the-bipolar-disorder-spotlight
0 · Reply
hiwatt
hiwatt Jul. 28 at 6:14 PM
$ALZN Noticed Alzn updated their clinical trial page today to say they started the BP study on 5-11. What I don't get is last year they did a PR 10 days after study started to announce first enrolled and 10 day after that another PR to announce first dosed. The stock went up 75% on the second PR. It has been 47 days since trial started and no PR. The good news is they didn't change study completion date and it's still set for 12-26 for now. They also did an 8K in March to announce delisting deadline. Apparently they got an extension but didn't bother to do an 8k to update shareholders, rather just put it in the 10K last week. I realize they operate on a shoestring budget, but can't the investor relations guy do a PR?
0 · Reply
topstockalerts
topstockalerts Jul. 25 at 1:26 AM
$ALZN the buyers seem unusually committed here.
0 · Reply
hiwatt
hiwatt Jul. 23 at 7:37 PM
$ALZN Looks like Alzn will skirt past the new Nasdaq delisting requirement for now, At least $5M marketcap or immediate suspension after 30 days. With 4.8 M shares at 1.30, that's $6.2M. They have until 9-16, unless granted an another extension, to get shareholder equity up. That's means they would have to partner with another biotech, which I don't see happening now, do a share deal with a private investor, or get share price up and sell more shares. They need at least $5M to see the BP trial thru results. Last year the stock jumped 75% when the first patient was dosed in the lithium brain study. If history repeats, that would help get to trials results.
0 · Reply
hiwatt
hiwatt Jul. 23 at 3:30 AM
$ALZN 10k negatives Only $700K cash as of 4-30-26. Material weakness, not enough bean counters. Almost 1M ATM shares sold, $800K accounted for as of 4-30-26 Death of board member, Lynne F McGrafth. Positives--Nasdaq granted listing extension until Sept 16, 26. ATM added $500K in last 2 months. Still saying BP results by years end??? Should get first patient dosed PR soon. Additional lithium in the brain data--Full pharmacokinetics and pharmacodynamic results are expected in August 2026.
0 · Reply
kshonstocks
kshonstocks Jul. 21 at 3:31 PM
100 dma b/o $ALZN
0 · Reply
AntoineChigurh
AntoineChigurh Jul. 16 at 1:13 PM
0 · Reply
gamer2k19
gamer2k19 Jul. 16 at 1:08 PM
$ALZN and $GPUS What do these two have in common? lol
1 · Reply
hiwatt
hiwatt Jul. 8 at 1:30 AM
$ALZN VRTX acquired CRNX today for $10B. They have one rare drug that treats around 20,000 and a second ratre drug that will treat around17,000. They had $18M in revenue and a negative -$339M in gross profit. Amazing $4B added in marketcap overnight.
0 · Reply
hiwatt
hiwatt Jul. 7 at 5:52 PM
$ALZN If only there was a biotech that had a lithium patent--Mental Health Drug Shows Promise in Arthritis Treatment Lithium chloride found to slow degradation. A drug commonly used to treat mental health issues may provide a promising new treatment to arthritis patients. A study conducted by researchers at Queen Mary University of London (QMUL) in collaboration with the University of Otago in New Zealand evaluated lithium chloride, which is commonly used as a mood stabilizer for people suffering from bipolar disorder, for the treatment of arthritis. The researchers examined the effect of lithium chloride on cartilage, which showed the drug is able to slow down degradation associated with osteoarthritis. Osteoarthritis causes degradation to joint cartilage, resulting in pain. The researchers concluded lithium chloride can prevent degradation and the loss of mechanical integrity in the cartilage of arthritis patients and that long-term dietary lithium use of lithium does not cause arthritis.
0 · Reply
hiwatt
hiwatt Jul. 7 at 5:37 PM
$ALZN If only there was a biotech that had a lithium patent---https://www.eds.clinic/articles/benefitis-low-dose-lithium
0 · Reply